Galenica Will Leverage Aspreva Acquisition To Strengthen Specialty Pharma Group
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss drug company seeks to buy Aspreva for roughly $915 million to accelerate development of its pharma arm.